See more : G6 Materials Corp. (GGG.V) Income Statement Analysis – Financial Results
Complete financial analysis of MannKind Corporation (MNKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MannKind Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- L’Air Liquide S.A. (AIL.DE) Income Statement Analysis – Financial Results
- Reeltime Rentals, Inc. (RLTR) Income Statement Analysis – Financial Results
- Nippon Sanso Holdings Corporation (TYNPF) Income Statement Analysis – Financial Results
- HKC International Holdings Limited (0248.HK) Income Statement Analysis – Financial Results
- Abacus Mining & Exploration Corporation (ABCFF) Income Statement Analysis – Financial Results
MannKind Corporation (MNKD)
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.96M | 99.77M | 75.44M | 65.14M | 63.04M | 27.86M | 11.75M | 174.76M | 0.00 | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Cost of Revenue | 62.77M | 57.50M | 38.86M | 24.64M | 27.98M | 20.48M | 17.23M | 50.09M | 140.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 136.19M | 42.27M | 36.59M | 40.50M | 35.06M | 7.38M | -5.48M | 124.67M | -140.41M | 0.00 | 0.00 | 35.00K | 50.00K | 93.00K | 0.00 | 20.00K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 154.00K |
| Gross Profit Ratio | 68.45% | 42.37% | 48.49% | 62.17% | 55.62% | 26.49% | -46.68% | 71.34% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 31.28M | 19.72M | 12.31M | 6.25M | 6.90M | 8.74M | 14.12M | 14.92M | 29.67M | 100.24M | 109.72M | 101.52M | 99.96M | 112.28M | 156.33M | 250.44M | 256.84M | 191.80M | 95.35M | 59.27M | 45.61M | 42.72M | 19.76M | 20.54M |
| General & Administrative | 42.54M | 37.72M | 31.89M | 22.88M | 0.00 | 79.72M | 74.96M | 27.07M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 51.78M | 53.75M | 45.53M | 34.37M | 0.00 | 0.00 | 0.00 | 19.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 94.31M | 91.47M | 77.42M | 59.04M | 74.67M | 79.72M | 74.96M | 46.93M | 108.40M | 79.38M | 59.68M | 45.47M | 40.63M | 40.31M | 53.45M | 55.34M | 50.52M | 42.00M | 22.78M | 17.88M | 20.70M | 13.22M | 0.00 | 4.85M |
| Other Expenses | 1.92M | -102.00K | 339.00K | 23.00K | -926.00K | -437.00K | 13.00K | -597.00K | 1.37M | 1.68M | -635.00K | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.60M | 111.19M | 90.07M | 65.29M | 81.57M | 88.44M | 88.86M | 59.58M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Cost & Expenses | 190.28M | 168.69M | 128.93M | 89.93M | 109.55M | 108.92M | 106.09M | 109.67M | 204.24M | 179.63M | 169.40M | 147.00M | 140.59M | 152.59M | 209.78M | 305.79M | 307.37M | 233.80M | 118.12M | 77.15M | 66.31M | 207.37M | 19.76M | 25.40M |
| Interest Income | 6.15M | 2.51M | 112.00K | 167.00K | 997.00K | 501.00K | 293.00K | 85.00K | 18.00K | 9.00K | 8.00K | 7.00K | 18.00K | 40.00K | 70.00K | 5.13M | 17.78M | 0.00 | 3.71M | 932.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.16M | 24.77M | 16.58M | 9.47M | 10.91M | 9.44M | 13.28M | 18.48M | 24.13M | 20.44M | 21.46M | 21.63M | 21.82M | 17.38M | 10.45M | 2.34M | 3.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.54M | 6.29M | 3.26M | 2.98M | 2.78M | 1.70M | 1.80M | 2.40M | 13.28M | 18.58M | 14.06M | 14.40M | 15.91M | 17.32M | 18.73M | 12.29M | 8.97M | 8.52M | 7.39M | 7.18M | 7.66M | 5.07M | 50.08M | -204.00K |
| EBITDA | 15.13M | -56.34M | -61.09M | -45.01M | -38.22M | -75.60M | -102.21M | 146.54M | -344.66M | -160.18M | -155.97M | -133.74M | -123.68M | -135.86M | -190.93M | -288.41M | -280.81M | -225.18M | -106.95M | -68.81M | -58.63M | -51.35M | 289.00K | -25.45M |
| EBITDA Ratio | 7.60% | -66.66% | -71.06% | -37.75% | -73.67% | -280.49% | -800.67% | 36.95% | 0.00% | 0.00% | 0.00% | -423,268.57% | -281,042.00% | -163,196.77% | 0.00% | -1,503,180.00% | -2,981,870.00% | -225,388.00% | 0.00% | 0.00% | 0.00% | 0.00% | 88.65% | -16,523.38% |
| Operating Income | 8.68M | -68.92M | -53.48M | -24.79M | -46.51M | -76.60M | -108.19M | 67.26M | -344.66M | -179.63M | -169.40M | -146.96M | -140.54M | -152.50M | -209.78M | -305.77M | -307.36M | -233.70M | -118.12M | -77.15M | -66.31M | -207.37M | -49.79M | -25.24M |
| Operating Income Ratio | 4.36% | -69.08% | -70.89% | -38.05% | -73.78% | -274.94% | -921.15% | 38.49% | 0.00% | 0.00% | 0.00% | -419,885.71% | -281,078.00% | -163,976.34% | 0.00% | -1,528,825.00% | -3,073,570.00% | -233,697.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15,273.62% | -16,390.91% |
| Total Other Income/Expenses | -19.06M | -23.29M | -33.90M | -9.55M | -7.31M | -10.14M | -9.09M | 58.40M | -23.79M | -18.76M | -22.09M | -22.81M | -20.27M | -18.06M | -10.33M | 2.73M | 14.17M | 3.15M | 3.79M | 1.16M | 434.00K | 1.10M | 1.55M | 583.00K |
| Income Before Tax | -10.38M | -87.40M | -80.93M | -57.46M | -51.90M | -86.74M | -117.28M | 125.66M | -368.45M | -198.38M | -191.49M | -169.77M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.54M | -114.34M | -75.99M | -65.88M | -206.26M | -48.24M | -24.66M |
| Income Before Tax Ratio | -5.22% | -87.60% | -107.27% | -88.20% | -82.34% | -311.34% | -998.57% | 71.91% | 0.00% | 0.00% | 0.00% | -485,068.57% | -321,608.00% | -183,397.85% | 0.00% | -1,515,185.00% | -2,931,870.00% | -230,543.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,798.47% | -16,012.34% |
| Income Tax Expense | 1.56M | 24.77M | 10.87M | -218.00K | 7.83M | 240.00K | 51.00K | 13.72M | 12.22M | 3.55M | 6.77M | -408.00K | 5.91M | 738.00K | -8.28M | 2.00K | 3.00K | 5.00K | 1.00K | 1.00K | 1.00K | 2.00K | 2.00K | 2.00K |
| Net Income | -11.94M | -112.17M | -91.79M | -57.24M | -59.73M | -86.98M | -117.33M | 125.66M | -368.45M | -198.38M | -191.49M | -169.37M | -160.80M | -170.56M | -220.10M | -303.04M | -293.19M | -230.55M | -114.34M | -75.99M | -65.88M | -206.27M | -48.25M | -24.66M |
| Net Income Ratio | -6.00% | -112.43% | -121.67% | -87.87% | -94.75% | -312.20% | -999.00% | 71.91% | 0.00% | 0.00% | 0.00% | -483,902.86% | -321,608.00% | -183,397.85% | 0.00% | -1,515,195.00% | -2,931,900.00% | -230,548.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,799.08% | -16,013.64% |
| EPS | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.37 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| EPS Diluted | -0.04 | -0.44 | -0.37 | -0.26 | -0.31 | -0.60 | -1.13 | 1.36 | -4.54 | -2.57 | -3.20 | -4.68 | -6.60 | -7.50 | -10.33 | -14.92 | -18.32 | -22.62 | -14.34 | -15.07 | -17.82 | -76.55 | -22.90 | -19.64 |
| Weighted Avg Shares Out | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 103.83M | 92.05M | 81.16M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
| Weighted Avg Shares Out (Dil) | 267.01M | 257.09M | 249.24M | 222.59M | 195.58M | 144.14M | 104.25M | 92.09M | 81.23M | 77.05M | 59.92M | 36.17M | 24.36M | 22.73M | 21.31M | 20.31M | 16.01M | 10.19M | 7.97M | 5.04M | 3.70M | 2.69M | 2.11M | 1.26M |
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Reached enrollment goal of 305 patients living with Type 1 or Type 2 diabetes Primary endpoint analysis expected in 4Q 2024 Data dissemination and FDA submission expected in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
MannKind sold a 10% stake in Tyvaso DPI for $150 million upfront, with an additional $50 million possible, indicating the potential value of the remaining 9% to be upwards of $1.8 billion. Liquidia's likely entry into the market with a...
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a sustained-release...
MoneyShow's Best Investment Ideas For 2024: Part 6
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed...
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI
MannKind Corp. MNKD, -1.62% said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $200 million. United Therapeutics Corp. licensed Tyvaso...
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder in exchange for up to $200 million,...
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its...
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
MannKind Corporation Reports 2023 Third Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs.
Source: https://incomestatements.info
Category: Stock Reports